{"id":"doi:10.1186/s13195-021-00939-9","kind":"article","title":"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231","authors":["Bayoumy S","Verberk IMW","den Dulk B","Hussainali Z","Zwan M","van der Flier WM","Ashton NJ","Zetterberg H","Blennow K","Vanbrabant J","Stoops E","Vanmechelen E","Dage JL","Teunissen CE"],"author_count":14,"year":2021,"published":"2021-12-04","venue":"Alzheimer's research & therapy","cited_by":174,"doi":"10.1186/s13195-021-00939-9","arxiv_id":null,"nct_id":null,"source_url":"https://doi.org/10.1186/s13195-021-00939-9","archive_url":"https://space-kitty.com/papers/doi:10.1186/s13195-021-00939-9","updated":null,"pmid":"34863295","pmcid":"PMC8645090","openalex_id":null,"pdf_url":"https://europepmc.org/articles/PMC8645090/pdf","abstract":"Introduction Studies using different assays and technologies showed highly promising diagnostic value of plasma phosphorylated (P-)tau levels for Alzheimer's disease (AD). We aimed to compare six P-tau Simoa assays, including three P-tau181 (Eli Lilly, ADx, Quanterix), one P-tau217 (Eli Lilly), and two P-tau231 (ADx, Gothenburg). Methods We studied the analytical (sensitivity, precision, parallelism, dilution linearity, and recovery) and clinical (40 AD dementia patients, age 66±8years, 50%F; 40 age- and sex-matched controls) performance of the assays. Results All assays showed robust analytical performance, and particularly P-tau217 Eli Lilly; P-tau231 Gothenburg and all P-tau181 assays showed robust clinical performance to differentiate AD from controls, with AUCs 0.936-0.995 (P-tau231 ADx: AUC = 0.719). Results obtained with all P-tau181 assays, P-tau217 Eli Lilly assay, and P-tau231 Gothenburg assay strongly correlated (Spearman's rho > 0.86), while correlations with P-tau231 ADx results were moderate (rho < 0.65). Discussion P-tau isoforms can be measured robustly by several novel high-sensitive Simoa assays.","abstract_license":"CC-BY (article license as recorded by Europe PMC; abstract reproduced unmodified apart from markup removal)","license":"CC-BY","is_open_access":true,"retracted":false,"peer_reviewed":null,"categories":[],"details":null,"provenance":"europepmc","attribution":"Abstract of \"Clinical and analytical comparison of six Simoa assays for plasma P-tau isoforms P-tau181, P-tau217, and P-tau231\" by Bayoumy S, Verberk IMW, den Dulk B et al., https://doi.org/10.1186/s13195-021-00939-9, used under its Creative Commons Attribution license (CC-BY); markup removed, otherwise unmodified.","topics":[{"slug":"neurodegeneration","name":"Alzheimer's, Parkinson's & Neurodegeneration","domain_slug":"medicine"}],"cited_in_dossiers":[]}